Floatz logo

tc011

Transformed Follicular Lymphoma (TFL)

TICAROS Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

209 Active assets in the Transformed Follicular Lymphoma (TFL) cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2/3BBB
Romidepsin
City of Hope Medical Center
Phase 2BBB
Recombinant Human Hyaluronidase
National Cancer Institute (NCI)
Phase 3BBB
Irinotecan
University of Michigan Rogel Cancer Center
Phase 2BBB
Busulphan
Masonic Cancer Center, University of Minnesota
Phase 2/3BBB

View all 50 →

Same molecule, other indications

tc011 is also rated in:

Follicular Lymphoma (FL)Dormant
B
Indicative ·
58 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
high grade B-cell lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →